15,793 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Purchased by Desjardins Global Asset Management Inc.

Desjardins Global Asset Management Inc. acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,793 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,943,000.

Several other large investors have also modified their holdings of JAZZ. Mackenzie Financial Corp boosted its stake in Jazz Pharmaceuticals by 2,278.4% during the fourth quarter. Mackenzie Financial Corp now owns 44,548 shares of the specialty pharmaceutical company’s stock worth $5,479,000 after buying an additional 42,675 shares during the period. Strs Ohio boosted its position in shares of Jazz Pharmaceuticals by 6.8% during the 4th quarter. Strs Ohio now owns 15,082 shares of the specialty pharmaceutical company’s stock worth $1,855,000 after purchasing an additional 963 shares during the period. Louisiana State Employees Retirement System acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at approximately $2,177,000. Cardinal Capital Management raised its position in Jazz Pharmaceuticals by 2.5% in the fourth quarter. Cardinal Capital Management now owns 10,230 shares of the specialty pharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 246 shares during the period. Finally, Kendall Capital Management lifted its stake in Jazz Pharmaceuticals by 29.9% during the fourth quarter. Kendall Capital Management now owns 7,799 shares of the specialty pharmaceutical company’s stock worth $959,000 after purchasing an additional 1,795 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, CFO Philip L. Johnson bought 12,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was bought at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.8 %

NASDAQ:JAZZ opened at $108.90 on Wednesday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24. Jazz Pharmaceuticals plc has a 1 year low of $108.75 and a 1 year high of $146.70. The stock has a market cap of $6.86 billion, a P/E ratio of 17.79, a P/E/G ratio of 1.53 and a beta of 0.59. The stock has a 50-day simple moving average of $120.99 and a 200-day simple moving average of $122.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. As a group, analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research reports. Piper Sandler lifted their price objective on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Truist Financial reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Needham & Company LLC reissued a “buy” rating and set a $220.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. HC Wainwright dropped their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating for the company in a report on Thursday, March 14th. Finally, Barclays reduced their target price on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, March 1st. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $195.08.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.